Chong Kun Dang Pharmaceutical Corp. (KRX: 185750)

Market Cap	1.23T
Revenue (ttm)	1.67T
Net Income (ttm)	212.79B
Shares Out	12.63M
EPS (ttm)	16,762.86
PE Ratio	5.79
Forward PE	n/a
Dividend	1,047.62 (1.09%)
Ex-Dividend Date	n/a

Volume	31,258
Open	96,200
Previous Close	96,000
Day's Range	95,100 - 97,600
52-Week Range	94,600 - 136,500
Beta	0.83
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 28, 2024

About Chong Kun Dang Pharmaceutical

Chong Kun Dang Pharmaceutical Corp. engages in the manufacturing, marketing, and sales of medicines in South Korea and internationally. It provides prescription drugs for anticancer, anti-hypertension, anti-hyperlipidemia, anti-diabetic, and immunosuppressant products; over-the-counter drugs for therapeutic benefits, supplements, and other preventive products; health supplements with preventive benefits, including prebiotics and vitamins with Omega-3; and consumer health products, such as red-ginseng healthy drink, hand sanitizer, and hair colo...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1941
• Employees: 2,286
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 185750

Financial Performance

In 2023, Chong Kun Dang Pharmaceutical's revenue was 1.67 trillion, an increase of 12.17% compared to the previous year's 1.49 trillion. Earnings were 212.52 billion, an increase of 162.52%.